Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anuradha Jayaram

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nature Reviews. Urology|June 3, 2015
Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancerAnuradha Jayaram, Gerhardt Attard
Cancer Discovery|April 4, 2018
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker TestAnuradha Jayaram, Daniel Wetterskog, Gerhardt Attard
JAMA Oncology|July 17, 2015
Cabozantinib-Getting Under the Skin of Cutaneous ToxicityAnuradha Jayaram, Zafeiris Zafeiriou, Johann S de Bono
Drugs|February 14, 2016
Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted AgentsZafeiris Zafeiriou, Anuradha Jayaram, Adam Sharp, et al.
Prostate Cancer and Prostatic Diseases|November 11, 2018
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented testEnrique González-Billalabeitia, Vincenza Conteduca, Daniel Wetterskog, et al.
BMC Medical Genomics|August 4, 2019
Identification of single nucleotide variants using position-specific error estimation in deep sequencing dataDimitrios Kleftogiannis, Marco Punta, Anuradha Jayaram, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2026
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancerAndrew Hudson, Anuradha Jayaram, Benjamin Garmezy, et al.
JAMA Oncology|June 30, 2018
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nature Reviews. Urology|June 3, 2015
Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancerAnuradha Jayaram, Gerhardt Attard
Cancer Discovery|April 4, 2018
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker TestAnuradha Jayaram, Daniel Wetterskog, Gerhardt Attard
JAMA Oncology|July 17, 2015
Cabozantinib-Getting Under the Skin of Cutaneous ToxicityAnuradha Jayaram, Zafeiris Zafeiriou, Johann S de Bono
Drugs|February 14, 2016
Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted AgentsZafeiris Zafeiriou, Anuradha Jayaram, Adam Sharp, et al.
Prostate Cancer and Prostatic Diseases|November 11, 2018
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented testEnrique González-Billalabeitia, Vincenza Conteduca, Daniel Wetterskog, et al.
BMC Medical Genomics|August 4, 2019
Identification of single nucleotide variants using position-specific error estimation in deep sequencing dataDimitrios Kleftogiannis, Marco Punta, Anuradha Jayaram, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2026
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancerAndrew Hudson, Anuradha Jayaram, Benjamin Garmezy, et al.
JAMA Oncology|June 30, 2018
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Pageof 3